Moerae Matrix, Inc.
Polyplex peptide delivery technology using cell-penetrating peptides to enable intracellular delivery of therapeutic and research peptides
- Sector
- Biotech
- Headquarters
- MORRISTOWN, NJ
- Latest Form D
- $5.5M, Jan 2013
- Total capital
- $5.8M
- Federal grants
- $225K
- 1 award · 2016
- Rank in peer group#254 of 392
- Private capital raised
- $5.5M
- 1 Form D · last Jan 2013
- 166 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 18 pending · first 2018
- Rank in peer group#20 of 392
Capital timeline
Latest events
- Federal grantNSF · Phase I · STTR Phase I: A Platform Reagent for the Intracellular Delivery of Positively Charged Peptide$225K
- Private capital raisedForm D · SEC · 1st filing$5.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#20 · top 5%
- Linked publications#19 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Cynthia LanderResearcherExecutive Officer, DirectorLinked by 6 patents · $225K in grants as PI
- Geoff DavisDirectorNamed in SEC Form D filings
- George DeVriesExecutive OfficerNamed in SEC Form D filings
- Jay SkylerDirectorNamed in SEC Form D filings
- Patrick ArensdorfExecutive OfficerNamed in SEC Form D filings
- Scott PaseltinerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 24- PendingInhibition Of Cardiac Fibrosis In Myocardial InfarctionUSPTOApplication 16460645
- GrantedCompositions And Methods For Preventing Or Treating Diseases, Conditions Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionUSPTOUS 10,562,947
- GrantedCompositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix DepositionUSPTOUS 10,500,249
Show all 24 patent records
- Inhibition Of Cardiac Fibrosis In Myocardial InfarctionJun 4, 2020 · Application 16460645Pending
- Compositions And Methods For Preventing Or Treating Diseases, Conditions Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionFeb 18, 2020 · US 10,562,947Granted
- Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix DepositionDec 10, 2019 · US 10,500,249Granted
- Inhibition Of Cardiac Fibrosis In Myocardial InfarctionJul 2, 2019 · US 10,336,788Granted
- Immunomodulatory Effect Of Inhaled Kinase Inhibitor Peptides In LungMay 9, 2019 · Application 16005408Pending
- Formulation Of MK2 Inhibitor PeptidesJan 31, 2019 · Application 16106504Pending
- Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionJan 24, 2019 · Application 15478950Pending
- Use Of MK2 Inhibitor Peptide-containing Compositions For Treating Non-small Cell Lung Cancer With SameJan 24, 2019 · Application 15977110Pending
- Formulation Of MK2 Inhibitor PeptidesOct 2, 2018 · US 10,087,225Granted
- Use Of Mks Inhibitor Peptide-containing Compositions For Treating Non-small Cell Lung Cancer With SameJun 19, 2018 · US 9,999,655Granted
- Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionFeb 13, 2018 · US 9,890,200Granted
- Compositions And Methods For Preventing Or Treating Chronic Lung Allograft Dysfunction (clad) And Idiopathic Pulmonary Fibrosis (ipf)Sep 17, 2015 · Application 14656492Pending
- Compositions and Methods for Treating Cutaneous ScarringMar 13, 2014 · Application 13829876Pending
- Immunomodulatory Effect Of Inhaled Kinase Inhibitor Peptides In LungApplication PCTUS2018036944Pending
- Therapeutic Uses Of Biocompatible Biogel CompositionsApplication PCTUS2009002117Pending
- Use Of MK2 Inhibitor Peptide-containing Compositions For Treating Non-small Cell Lung Cancer With SameApplication PCTUS2016021843Pending
- Formulation Of MK2 Inhibitor PeptidesApplication PCTUS2016012650Pending
- Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionApplication PCTUS2015061118Pending
- Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionApplication PCTUS2015047390Pending
- Compositions And Methods For Preventing Or Treating Chrinic Lung Allograft Dysfunction (clad) And Idiopathic Pulmonary Fibrosis (ipf)Application PCTUS2015020263Pending
- Compositions And Methods For Preventing Or Treating Chronic Lung Allograft Dysfunction (clad) And Idiopathic Pulmonary Fibrosis (ipf)Application 61953438Pending
- Compositions And Methods For Treating Cutaneous ScarringApplication PCTUS2013059060Pending
- Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix DepositionApplication PCTUS2012033368Pending
- Polypeptide For Treating Or Preventing AdhesionsApplication PCTUS2009061345Pending
Recent research by its founders
- Nebulized Delivery of the MAPKAP Kinase 2 Peptide Inhibitor MMI-0100 Protects Against Ischemia-Induced Systolic Dysfunction20200 cites
- An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles201987 cites
- MMI‐0100 Inhibits Cardiac Fibrosis in a Mouse Model Overexpressing Cardiac Myosin Binding Protein C201715 cites
Related companies, and why
- MOERAE MATRIX INCShares a founder: Cynthia Lander
- BLOOD CELL TECHNOLOGIES LLCSimilar federal contract value in Biotech · null in contracts
- OSEL, INC.Similar federal contract value in Biotech · null in contracts
- ELYSIUM HEALTH, INC.Similar federal contract value in Biotech · null in contracts
- Rondo TherapeuticsSimilar federal contract value in Biotech · null in contracts
- GROW BIOMEDICINE LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .